Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

News SummaryMost relevantAll newsSector newsTweets 
Latest news on ROCHE HOLDING LTD.
10:38a THE BUSINESS RESEARCH COMPANY : Asia accounted for $307 billion in the pharmaceu..
10:11a REMINDER : Invitation to Roche Analyst Event at ASCO 2017
07:24a ROCHE : FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cel..
05/20 ROCHE : Federal Contracts Awarded to Companies in Indiana (May 20)
05/20 ROCHE : Federal Contracts Awarded by Federal Agencies in Texas (May 20)
05/20 ROCHE : MILITARY $9.72 Million Federal Contract Awarded to Roche Diagnostics
05/20 ROCHE : builds case for T-cell bispecific-anti-PD-L1 combo
05/19 European shares claw back gains after worst week in six months
05/19 FOUNDATION MEDICINE : and Its Collaborators to Present New Data at ASCO 2017 Sup..
05/18 CHUGAI PHARMACEUTICAL : Results of the J-ALEX Study for Chugai's Alecensa® are P..
05/18 INVITATION : Roche Analyst Event at ISTH 2017
05/18 ROCHE : presents the first Phase I efficacy and safety data on CEA-TCB (CEA CD3 ..
05/17 ROCHE : Stand Up To Cancer Announces Second SU2C Catalyst Collaboration with Gen..
05/16 ROCHE : Atlantic City Library Concert Series
05/16 ROCHE : Genoa scores $62M Series A to take IPF drug into the clinic
05/16 ROCHE : Combine Solicitation - Roche MagNA Pure 96 DNA and Viral RNA Large Volum..
05/16 Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member o..
05/15 ROCHE : Structural shell work
05/12 AstraZeneca shares surge after key drug shows promise in lung cancer trial
05/12 ASTRAZENECA PLC (ADR) (NYSE : AZN) Severe Asthma Therapy Fails To Attain Primary..
05/12 HANMIPHARM : Hanmi Pharmaceutical Receives Approval of 1st-Phase Clinical Test
05/12 ROCHE : AstraZeneca reveal two separate late-stage failures
05/12 ROCHE : Genentech to Present New Data on Personalized Medicines and Cancer Immun..
05/11 ROCHE : Roches Tecentriq fails to boost survival in bladder cancer study
05/11 ROCHE : to present new data on personalised medicines and cancer immunotherapies..
05/11 GENENTECH : to Present New Data on Personalized Medicines and Cancer Immunothera..
05/10 ROCHE : provides update on phase III study of TECENTRIQ® (atezolizumab) in peopl..
05/10 AstraZeneca asthma drug fails, after similar setback at Roche
05/10 GENENTECH : Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) in Pe..
05/10 FOUNDATION MEDICINE : Precision Medicine Improves Treatment Outcomes for Some Pa..
05/09 FOUNDATION MEDICINE : reports 1Q loss
05/09 FOUNDATION MEDICINE, INC. : Results of Operations and Financial Condition, Finan..
05/09 FOUNDATION MEDICINE, INC. (NAS : FMI) Files An 8-K Results of Operations a..
05/08 ROCHE : La Roche College Honors 52nd Graduating Class
05/08 ROCHE : Presolicitation - Roche reagents and consumables
05/08 ROCHE : Presolicitation Notice - Roche reagents and consumables
05/08 ROCHE : launches AVENIO ctDNA Analysis Kits for Oncology Research
05/08 ROCHE : Historic Buildings In Park Ridge Park Recommended For Landmark Status
05/07 ROCHE : Roebuck working on power numbers, defense in sophomore year at La Roche
05/05 ROCHE : receives FDA approval for bladder cancer biomarker assay
05/05 ROCHE : FDA approves Roches high-volume immunoassay
05/04 ROCHE : FDA approves Roche's high-volume immunoassay
05/04 SAVE THE DATE : Roche Analyst Event at ISTH 2017
05/02 CORVUS PHARMACEUTICALS, INC. (NASDAQ : CRVS) Files An 8-K Entry into a Material ..
05/02 AstraZeneca immunotherapy wins first approval in bladder cancer
04/30 ROCHE : College results
04/28 CHUGAI PHARMACEUTICAL : Notice regarding Cancellation of Treasury Stocks
04/28 ROCHE : F. Hoffmann-La Roche Announces First Quarter Sales 2017
04/28 ROCHE : Special Notice - Roche Cobas TaqMan 48 Analyzer and Consumables
04/28 Celltrion wins Herceptin patent trials against Roche in Korea
04/27 Bristol-Myers Squibb Enters into Separate Agreements with Biogen and Roche to..
04/27 HOLOGIC : Findings from Hologic, Inc. in the Area of Viral Load Described (Analy..
04/27 ROCHE : reports a good start in 2017
04/27 ROCHE : Q1 sales boosted by 2 new cancer medicines
04/27 ROCHE : New data at AAN reinforce clinical benefit of Roches OCREVUS (ocrelizuma..
04/27DJROCHE : Revenue Up 4% at CHF12.94 Billion on Strong Sales
04/26 CHUGAI PHARMACEUTICAL : Notice regarding Cancellation of Treasury Stocks
04/26 ROCHE : New Data at AAN Reinforce Clinical Benefit of Genentech's Ocrevus (Ocrel..
04/26 ROCHE : CCI rules in favour of Biocon in case against Roche over breast cancer d..
04/26 ROCHE : New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (oc..
04/26 ROCHE : New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS ..
04/26 ROCHE : Cci orders probe against pharma major roche
04/26 ROCHE : Cci to investigate roche over breast cancer drug
04/25 ROCHE : Launches HPV Test in Europe
04/24 ROCHE : Pharmaceutical Freeze Drying Experts Gather in 2 weeks to discuss the Es..
04/21 INSIDER TRADING ACTIVITY FOUNDATION : FMI) – COO Sold 4,405 shares of Sto..
04/20 CHUGAI PHARMACEUTICAL : Reports Summarize Immunoglobulins Study Results from Chu..
04/20ROCHE HOLDING LTD. : quaterly sales release
04/20 REMINDER : Invitation to Roche’s First Quarter Sales 2017 Conference Call
04/19 ROCHE : FDA Grants Genentech's Tecentriq (Atezolizumab) Accelerated Approval as ..
04/19 ROCHE : Genentech Announces Positive Interim Results for Emicizumab in Phase III..
04/19 ROCHE : Genentech`s Tecentriq receives FDA-accelerated approval for advanced bla..
04/19 ROCHE : FDA grants Roche's TECENTRIQ® (atezolizumab) accelerated approval as ini..
04/19 ROCHE : FDA approves Roche's Lucentis (ranibizumab injection) for diabetic retin..
1  2  3  4  5  6  7  8  9  10Next
Financials ( CHF)
Sales 2017 53 401 M
EBIT 2017 18 668 M
Net income 2017 11 632 M
Debt 2017 8 699 M
Yield 2017 3,21%
P/E ratio 2017 19,46
P/E ratio 2018 17,72
EV / Sales 2017 4,49x
EV / Sales 2018 4,16x
Capitalization 231 250 M
More Financials
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 291  CHF
Spread / Average Target 8,6%
Consensus details
EPS Revisions
More Estimates Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.23%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.11%191 279
MERCK & CO., INC.8.78%175 160
More Results